Endometrial disorders in 406 breast cancer patients on tamoxifen: The case for less intensive monitoring

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 101, Issue 1, 2002, Pages 58-63

  Vosse, M ^a   Renard, F ^a   Coibion, M ^a   Neven, P ^b   Nogaret, J M ^a   Hertens, D ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Saint Jean Clinic of Brussels   (Belgium)

Author keywords

Endometrial disorder; Endometrial neoplams; Follow up strategy; Tamoxifen; Transvaginal ultrasonography

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; HYSTEROSCOPY; MAJOR CLINICAL STUDY; POLYP; POSTMENOPAUSE; PRIORITY JOURNAL; SCREENING; TRANSVAGINAL ECHOGRAPHY;

EID: 0037050789     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(01)00516-4     Document Type: Article

References (31)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
3. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer
4. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
5. Endometrial carcinoma and tamoxifen: Clearing up a controversy
6. Tamoxifen and the uterus and endometrium
7. Endometrial lesions in patients undergoing tamoxifen therapy
8. Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients
9. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
10. Surveillance for endometrial cancer in women receiving tamoxifen
11. Gynecologic effects of tamoxifen and the association with endometrial carcinoma
12. Benign and hyperplastic endometrial changes associated with tamoxifen use
13. Should tamoxifen users be screened for endometrial lesions?
14. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen
15. Endometrial thickness in tamoxifen-treated patients: Correlation with clinical and pathologic findings
16. Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients
17. Longitudinal hysteroscopic follow-up during tamoxifen treatment
18. Endometrial thickness in tamoxifen-treated patients: An independent predictor of endometrial disease
19. Risk of endometrial cancer after tamoxifen treatment of breast cancer
20. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients
21. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients
22. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features
23. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis
24. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies
25. Tamoxifen and endometrial cancer
26. Re: Tamoxifen: The need for a monitoring protocol
27. Endometrial evaluation prior to tamoxifen: Preliminary results of a prospective study
28. Uterine side effects of tamoxifen: A need for systematic pretreatment screening
29. Prevention of breast cancer in high-risk women
30. The effect of tamoxifen on the endometrium
31. Guidelines for monitoring patients taking tamoxifen treatment